Approximately 90 percent of women have cellulite, regardless of body shape or size. Although individuals can use topical treatments, such as lotions, creams, and scrubs to reduce temporarily the appearance of cellulite, more permanent and dramatic results have only been achieved through surgical and invasive procedures. However, a new, non-invasive and highly effective option has entered the playing field: Endo Aesthetics’s Qwo (collagenase clostridium histolyticum-aaes), the first injectable treatment for cellulite to be approved by the U.S. Food and Drug Administration (FDA). When injected, QWO is thought to enzymatically release the fibrous connective tissue responsible for drawing the skin downward and creating cellulite’s “dimpling” effect. The treatment is currently indicated to treat moderate-to-severe cellulite of the buttocks in adult women and is expected to be available throughout the U.S. at aesthetic healthcare practitioners’ offices by spring 2021. "Endo recognized a significant unmet need for an effective and non-invasive injectable treatment for cellulite, which led us to conduct the largest clinical trials in the history of cellulite investigation in the United States," says Matthew Davis, M.D., R.Ph., senior vice president and chief medical officer of Endo. "Supported by rigorous research, testing and development processes, we are proud to have received FDA approval of the first injectable treatment for cellulite in the buttocks and we look forward to delivering QWO to the aesthetics community and their adult female patients."